Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 11/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 16/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10081725 | 1.00 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL28546663 | 0.87 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17339718 | 0.84 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29194902 | 0.79 | PDE4B (0.46) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL724781 | 0.79 | KMT2A (0.38) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16774566 | 0.76 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL30930191 | 0.76 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3548545 | 0.72 | PDE4B (0.80) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2792660 | 0.71 | PDE4B (0.69) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2792654 | 0.71 | PDE4B (0.69) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016800-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | UNIVERSITY OF SOUTHERN CALIFORNIA | 2024-01-18 | — | — | US | claimed |
| US-20230405125-A1 | TREATMENT OF RECURRENT GIOBLASTOMA WITH PERILLYL ALCOHOL | Neonc Technologies, Inc. | 2023-12-21 | — | — | US | claimed |
| CN-116615197-A | Treatment of recurrent glioblastoma with perillyl alcohol | NeOnc技术股份有限公司 | 2023-08-18 | — | — | CN | claimed |
| US-20220054481-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | UNIVERSITY OF SOUTHERN CALIFORNIA | 2022-02-24 | — | — | US | claimed |
| US-11147809-B2 | Methods of treating neurofibromatosis with perillyl alcohol | Neonc Technologies, Inc. (US) | 2021-10-19 | — | — | US | claimed |
| US-11077104-B2 | Pharmaceutical compositions comprising POH derivatives | Neonc Technologies, Inc. (US) | 2021-08-03 | — | — | US | claimed |
| US-11013804-B2 | Pharmaceutical compositions comprising POH derivatives | NeOncTechnologies, Inc. (US) | 2021-05-25 | — | — | US | claimed |
| CN-105078973-B | Pharmaceutical composition comprising POH derivative | 尼昂克技术公司 | 2020-10-09 | — | — | CN | claimed |
| US-20200078462-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA | 2020-03-12 | — | — | US | claimed |
| US-20190167669-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | UNIVERSITY OF SOUTHERN CALIFORNIA | 2019-06-06 | — | — | US | claimed |
| US-20170128578-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. | 2017-05-11 | — | — | US | claimed |
| EP-2898883-B1 | Pharmaceutical compositions comprising perillyl alcohol carbamates | NEONC TECHNOLOGIES INC (US) | 2016-11-23 | — | — | EP | claimed |
| US-9499461-B2 | Pharmaceutical compositions comprising POH derivatives | Neonc Technologies, Inc. (US) | 2016-11-22 | — | — | US | claimed |
| EP-2609064-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DERIVATIVES OF PERILLYL ALCOHOL | NEONC TECHNOLOGIES INC (US) | 2016-09-28 | — | — | EP | claimed |
| WO-2016115147-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2016-07-21 | — | — | WO | claimed |
| US-20160038600-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NATIONAL INSTITUTES OF HEALTH | 2016-02-11 | — | — | US | claimed |
| EP-2898883-A1 | Pharmaceutical compositions comprising perillyl alcohol carbamates | Neonc Technologies Inc. (US) | 2015-07-29 | — | — | EP | claimed |
| US-20130210877-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2013-08-15 | — | — | US | claimed |
| EP-2609064-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | Neonc Technologies Inc. (US) | 2013-07-03 | — | — | EP | claimed |
| WO-2012027693-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | NEONC TECHNOLOGIES INC. (US) | 2012-03-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038600-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PDE3A, PDE3B, PDE5A | PDE4A 10/4885PDE4B 15/4885PDE4C 21/4885 |
| US-20170128578-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, DOHH | PDE4A 1501/4885PDE4B 1525/4885PDE4C 1565/4885 |
| US-20220054481-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | PMP22, CHAT, REL | PDE4A 874/4885PDE4B 1540/4885PDE4C 1374/4885 |
| US-20190167669-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | PMP22, CHAT, REL | PDE4A 874/4885PDE4B 1540/4885PDE4C 1374/4885 |
| US-11147809-B2 | Methods of treating neurofibromatosis with perillyl alcohol | PMP22, CHAT, REL | PDE4A 874/4885PDE4B 1540/4885PDE4C 1374/4885 |
| US-11077104-B2 | Pharmaceutical compositions comprising POH derivatives | PLIN3, PLIN5, DOHH | PDE4A 1501/4885PDE4B 1525/4885PDE4C 1565/4885 |
| US-20240016800-A1 | METHODS OF TREATING NEUROFIBROMATOSIS WITH PERILLYL ALCOHOL | PMP22, CHAT, REL | PDE4A 874/4885PDE4B 1540/4885PDE4C 1374/4885 |
| US-20230405125-A1 | TREATMENT OF RECURRENT GIOBLASTOMA WITH PERILLYL ALCOHOL | IDH3A, IDH1, IDH3B | PDE4A 3894/4885PDE4B 4120/4885PDE4C 4407/4885 |
| US-20200078462-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PDE3A, PDE3B, PDE5A | PDE4A 10/4885PDE4B 15/4885PDE4C 21/4885 |
| US-11013804-B2 | Pharmaceutical compositions comprising POH derivatives | PDE3A, PDE3B, PDE5A | PDE4A 10/4885PDE4B 15/4885PDE4C 21/4885 |
| US-20130210877-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, DOHH | PDE4A 1501/4885PDE4B 1525/4885PDE4C 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.